In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IND Over POC: The New Sweet Spot For Biopharma Dealmaking

Executive Summary

Though clinical proof-of-concept has long been the goal of fledgling biotechs hoping to land a deep-pocketed partner or acquirer, data suggest reaching this inflection point may no longer provide an optimal risk-reward balance. Biotechs would be wise to partner earlier.

You may also be interested in...



Reinventing Flexion For The World Beyond Proof-Of-Concept

Flexion Therapeutics had the pedigree, determination, and corporate connections to source and speed to clinical proof-of-concept its in-licensed pharma assets, and it planned to build a business around getting paid to do so. But a funny thing happened on the way to the bank.

Biopharmaceutical Trends In 2012: Regulatory And Market Strides Paper Over Existential Dilemmas

The biopharma industry enjoyed regulatory success in 2012 that was recognized by investors. The stench from the carcasses of industry’s genericized blockbusters has begun to fade, but R&D productivity for the most part remains poor, expensive late-stage failures abound, and industry is still searching for sustainable business models.

Deals Of The Week: Novartis/Enanta, Ligand/Retrophin, Auxilium/Actelion, Amgen/Dako

A prosaic week in biopharma deal-making leads DOTW to ponder a brain-computer interface specialist’s efforts to apply its technology to patients with severe communication limitations.

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel